2-[(E)-(4-chloro-3-fluorophenyl)methylideneamino]guanidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(E)-(4-chloro-3-fluorophenyl)methylideneamino]guanidine
• 化学式: C₈H₈ClFN₄
• 分子量: 214.63
• InChiKey: BTQQFTMAKZGAFZ-YIXHJXPBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.8
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Inhibitors and their uses
  申请人：MEDICAL RESEARCH COUNCIL

  公开号：US11154519B2

  公开（公告）日：2021-10-26

  The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.

  本发明涉及PPP1 R15A和PPP1 R15B的抑制剂及其在治疗中的用途，特别是在治疗通过抑制PPP1 R15A和PPP1 R15B而减轻的疾病状态中的用途，例如与错误折叠蛋白的积累或蛋白抑制紊乱有关的疾病。本发明的化合物包括具有式 IA 的化合物或其药学上可接受的盐，其中 R1a、R3a、R5a、Xa 和 Ya 如本文所定义。
• INHIBITORS AND THEIR USES
  申请人：United Kingdom Research and Innovation

  公开号：EP3280405B1

  公开（公告）日：2021-07-07
• COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS
  申请人：Chow Suk Hen

  公开号：US20150246140A1

  公开（公告）日：2015-09-03

  In some aspects, the invention relates to methods of treating conditions associated with sleep disorders, comprising administering an agent that modulates the activity of a neuropeptide receptor or a neuropeptide receptor ligand. In some aspects, the invention relates to methods of screening agents that modulate the activity of a neuropeptide receptor in an organism, optionally using cells or organisms comprising a genetic modification that affects a neuropeptide signaling pathway. In some aspects, the invention relates to methods of characterizing a condition associated with a sleep disorder comprising sequencing a nucleic acid encoding either a neuropeptide receptor or a neuropeptide receptor ligand and comparing the sequence with a reference sequence.
• [EN] COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULENESS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DESTINÉS À MODULER LE SOMMEIL ET L'ÉTAT DE VEILLE
  申请人：CALIFORNIA INST OF TECHN

  公开号：WO2015120446A1

  公开（公告）日：2015-08-13

  In some aspects, the invention relates to methods of treating conditions associated with sleep disorders, comprising administering an agent that modulates the activity of a neuropeptide receptor or a neuropeptide receptor ligand. In some aspects, the invention relates to methods of screening agents that modulate the activity of a neuropeptide receptor in an organism, optionally using ceils or organisms comprising a genetic modification that affects a neuropeptide signaling pathway. In some aspects, the invention relates to methods of characterizing a condition associated with a sleep disorder comprising sequencing a nucleic acid encoding either a neuropeptide receptor or a neuropeptide receptor ligand and comparing the sequence with a reference sequence.
• [EN] INHIBITORS AND THEIR USES<br/>[FR] INHIBITEURS ET LEURS UTILISATIONS
  申请人：MEDICAL RES COUNCIL

  公开号：WO2016162689A1

  公开（公告）日：2016-10-13

  The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Yaare as defined herein.